Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1β and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1β which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1β which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Rα receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1β, IL-6, TNF and CCL2. The suppression of IL-1β by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1β and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy.
Keywords: COVID-19; IL-1; IL-6; pro-inflammatory cytokines; COVI-19; SARS-CoV-2.
Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment.J Gen Virol. 2013 Dec;94(Pt 12):2679-2690. doi: 10.1099/vir.0.055533-0. Epub 2013 Sep 28. J Gen Virol. 2013. PMID: 24077366
How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.J Biol Regul Homeost Agents. 2020 Mar 31;34(2). doi: 10.23812/Editorial-Conti-2. Online ahead of print. J Biol Regul Homeost Agents. 2020. PMID: 32228825
An Allergic Lung Microenvironment Suppresses Carbon Nanotube-Induced Inflammasome Activation via STAT6-Dependent Inhibition of Caspase-1.PLoS One. 2015 Jun 19;10(6):e0128888. doi: 10.1371/journal.pone.0128888. eCollection 2015. PLoS One. 2015. PMID: 26091108 Free PMC article.
Features, Evaluation and Treatment Coronavirus (COVID-19).2020 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
Coronavirus virulence genes with main focus on SARS-CoV envelope gene.Virus Res. 2014 Dec 19;194:124-37. doi: 10.1016/j.virusres.2014.07.024. Epub 2014 Aug 2. Virus Res. 2014. PMID: 25093995 Free PMC article. Review.